Q
Qiuping Xiang
Researcher at Guangzhou Institutes of Biomedicine and Health
Publications - 24
Citations - 405
Qiuping Xiang is an academic researcher from Guangzhou Institutes of Biomedicine and Health. The author has contributed to research in topics: Bromodomain & Prostate cancer. The author has an hindex of 7, co-authored 16 publications receiving 279 citations. Previous affiliations of Qiuping Xiang include Chinese Academy of Sciences.
Papers
More filters
Journal ArticleDOI
ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
Junjian Wang,June X. Zou,Xiaoqian Xue,Demin Cai,Yan Zhang,Zhijian Duan,Qiuping Xiang,Joy C. Yang,Maggie C. Louie,Alexander D. Borowsky,Allen C. Gao,Christopher P. Evans,Kit S. Lam,Jianzhen Xu,Hsing Jien Kung,Ronald M. Evans,Yong Xu,Hongwu Chen,Hongwu Chen +18 more
TL;DR: ROR-γ is established as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa by suppressing tumor growth and driving AR expression in the tumors.
Journal ArticleDOI
Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation
Xiaoqian Xue,Yan Zhang,Liu Zhaoxuan,Liu Zhaoxuan,Ming Song,Yanli Xing,Yanli Xing,Qiuping Xiang,Qiuping Xiang,Zhen Wang,Zhengchao Tu,Y. Zhou,Ke Ding,Yong Xu +13 more
TL;DR: The identification, optimization, and evaluation of benzo[cd]indol-2(1H)-one containing compounds as a new class of BET bromodomain inhibitors, starting from structure-based virtual screening (SBVS).
Journal ArticleDOI
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Qiuping Xiang,Chao Wang,Yan Zhang,Xiaoqian Xue,Ming Song,Cheng Zhang,Chenchang Li,Chun Wu,Kuai Li,Xiaoyan Hui,Yulai Zhou,Jeff B. Smaill,Adam V. Patterson,Donghai Wu,Ke Ding,Yong Xu +15 more
TL;DR: The identification, optimization and evaluation of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 inhibitors starting from fragment-based virtual screening (FBVS) and a cocrystal structure of the inhibitor (22e) in complex with CBP provides a solid structural basis for further optimization.
Journal ArticleDOI
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC)
Zhang Maofeng,Zhang Maofeng,Yan Zhang,Yan Zhang,Ming Song,Xiaoqian Xue,Xiaoqian Xue,Junjian Wang,Chao Wang,Cheng Zhang,Cheng Zhang,Chenchang Li,Chenchang Li,Qiuping Xiang,Qiuping Xiang,Lingjiao Zou,Lingjiao Zou,Xishan Wu,Xishan Wu,Chun Wu,Baijun Dong,Wei Xue,Y. Zhou,Hongwu Chen,Donghai Wu,Ke Ding,Yong Xu +26 more
TL;DR: The design, optimization, and evaluation of benzo[ d]isoxazole-containing compounds as potent BET bromodomain inhibitors represent a new class of compounds for the development of potential therapeutics against CRPC.
Journal ArticleDOI
Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Lingjiao Zou,Qiuping Xiang,Qiuping Xiang,Xiaoqian Xue,Cheng Zhang,Cheng Zhang,Chenchang Li,Chao Wang,Chao Wang,Qiu Li,Qiu Li,Rui Wang,Shuang Wu,Shuang Wu,Yulai Zhou,Yan Zhang,Yan Zhang,Yong Xu +17 more
TL;DR: Y08197, a novel 1-(indolizin-3-yl) ethanone derivative, is identified as a selective inhibitor of CBP/EP300 bromodomain and explored its antitumor activity against prostate cancer cell lines in vitro.